Arca
Skip to content
Tools
Tools

PDGFRA, PDGFRB: Platelet-derived growth factor receptor

Complex in Homo sapiens that 25 drugs act on.

  • Drugs that act on it: 25
  • Approved: 7
  • In phases 1 to 3: 18
  • Sponsors: 21

Who is on it, and how far along

Every drug ChEMBL records acting on PDGFRA, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 22
  • Protein or peptide 1
  • Other 2

Approved7

  • Regorafenib
  • Sunitinib
  • Pazopanib
  • Nintedanib
  • Quizartinib
  • Midostaurin
  • Becaplermin

Phase 310

  • Famitinib
  • Cediranib
  • Motesanib
  • Masitinib
  • Seralutinib
  • Crenolanib
  • Dovitinib
  • Linifanib
  • Orantinib
  • Vatalanib

Phase 27

  • ENMD-981693
  • Foretinib
  • Ilorasertib
  • SU-014813
  • X-82
  • XL-820
  • XL-999

Phase 11

  • TAK-593

Sponsors

Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

The landscape

Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 24 of 25 act as: Platelet-derived growth factor receptor inhibitor; the rest name their own mechanism.
RegorafenibBoxed warningApprovedBayerSmall moleculeInhibitor96
SunitinibBoxed warningApprovedCPPI CVSmall moleculeInhibitor54
PazopanibBoxed warningApprovedNovartis PharmaceuticalsSmall moleculeInhibitor27
NintedanibApprovedCSPC Pharmaceutical GroupSmall moleculeInhibitor26
QuizartinibBoxed warningApprovedDaiichi SankyoSmall moleculeInhibitor19
MidostaurinApprovedNovartis PharmaceuticalsSmall moleculeInhibitor16
BecaplerminApprovedSmith & NephewProtein or peptideAgonistPlatelet-derived growth factor receptor agonist4
FamitinibPhase 3Jiangsu Hengrui MedicineSmall moleculeInhibitor28
CediranibPhase 3AstraZeneca PharmaceuticalsSmall moleculeInhibitor18
MotesanibPhase 3GERONSmall moleculeInhibitor8
MasitinibPhase 3AB ScienceSmall moleculeInhibitor3
SeralutinibPhase 3Gossamer BioSmall moleculeInhibitor1
CrenolanibPhase 3Arog PharmaceuticalsSmall moleculeInhibitor0
DovitinibPhase 3Novartis PharmaceuticalsSmall moleculeInhibitor0
LinifanibPhase 3AbbVieSmall moleculeInhibitor0
OrantinibPhase 3Taiho Pharmaceutical Co., Ltd.Small moleculeInhibitor0
VatalanibPhase 3Novartis PharmaceuticalsSmall moleculeInhibitor0
ENMD-981693Phase 2CASI PharmaceuticalsSmall moleculeInhibitor0
ForetinibPhase 2GSKSmall moleculeInhibitor0
IlorasertibPhase 2AbbVieSmall moleculeInhibitor0
SU-014813Phase 2PfizerSmall moleculeInhibitor0
X-82Phase 2TyrogenexOtherInhibitor0
XL-820Phase 2ExelixisOtherInhibitor0
XL-999Phase 2Symphony Evolution, Inc.Small moleculeInhibitor0
TAK-593Phase 1Takeda Pharmaceuticals USASmall moleculeInhibitor0

Open trials

The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 76 in all, from ClinicalTrials.gov.
Prospective Evaluation of Response to Treatment in Younger Adult Patients (18-60 Years) With Acute Myeloid Leukemia (AML)Midostaurin, QuizartinibPhase 3Not yet recruitingUniversity Hospital, ToulouseNov 19, 2026
A Post-Marketing Trial to Evaluate the Safety and Efficacy of Quizartinib in Chinese Participants With Newly Diagnosed FMS-like Tyrosine Kinase 3-internal Tandem Duplication [FLT3-ITD] (+) Acute Myeloid Leukemia (AML)QuizartinibPhase 4Not yet recruitingDaiichi Sankyo Europe, GmbH, a Daiichi Sankyo CompanyNov 19, 2026
Yangyin Qingfei Decoction for Radiation Pneumonitis PreventionNintedanibPhase 2Not yet recruitingThe First Affiliated Hospital of Zhejiang Chinese Medical UniversityNov 17, 2026
A Trial Evaluating Two Imetelstat Doses in Participants With Lower Risk Myelodysplastic Syndrome (MDS)MotesanibPhase 4Not yet recruitingGeron CorporationNov 16, 2026
A Multicenter, Randomized, Blinded, Placebo- and Active-Controlled Phase II Study to Evaluate the Efficacy and Safety of SYH9061 in Adult Patients With Idiopathic Pulmonary FibrosisNintedanibPhase 2Not yet recruitingCSPC-NBP Pharmaceutical Co., Ltd.Nov 12, 2026
Phase 2 Evaluation of Recombinant Human Platelet-Derived Growth Factor-BB (rhPDGF-BB) Injection for the Treatment of Infraorbital HollowingBecaplerminPhase 2Not yet recruitingLynch Regenerative MedicineNov 4, 2026
Liver Transplantation Versus Conventional Medical Therapy for Low-Grade GEP-NET With Liver MetastasesSunitinib—Enrolling by invitationChiyi ChenNov 3, 2026
Maintenance Treatment With Imetelstat in Patients With High-Risk Myeloid Neoplasms After Allo-SCTMotesanibPhase 1Not yet recruitingUniversity of Wisconsin, MadisonNov 2, 2026
Adebrelimab Plus Famitinib as Adjuvant Therapy in Non-pCR NSCLCFamitinibPhase 2Not yet recruitingRuijin HospitalOct 22, 2026
Benmelstobart Plus Anlotinib Versus Sunitinib as First-Line Treatment for Advanced Non-Clear Cell Renal Cell CarcinomaSunitinibPhase 3Active, not recruitingSun Yat-sen UniversityOct 20, 2026
Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizartinib Compared to the Usual Treatment of Cytarabine, Daunorubicin, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)QuizartinibPhase 2Not yet recruitingNational Cancer Institute (NCI)Oct 7, 2026
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6088 in Patients With Advanced/Metastatic Solid TumorsRegorafenibPhase 1 / Phase 2Not yet recruitingCSPC Megalith Biopharmaceutical Co.,Ltd.Oct 5, 2026
First-Line Systemic Therapies in Advanced Renal Cell Carcinoma in SpainPazopanib, Sunitinib—Active, not recruitingBristol-Myers SquibbOct 1, 2026
Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II TrialFamitinibPhase 2RecruitingThe First Affiliated Hospital with Nanjing Medical UniversitySep 29, 2026
Retlirafusp Alfa Combined With Famitinib, Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Unresectable Pancreatic CancerFamitinibPhase 2Not yet recruitingThe First Affiliated Hospital of Zhengzhou UniversitySep 11, 2026
Adebrelimab With Famitinib and Chemotherapy as Neoadjuvant Therapy for ESCCFamitinibPhase 2RecruitingFirst Affiliated Hospital Xi'an Jiaotong UniversityAug 31, 2026
Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast CancerRegorafenibPhase 2Not yet recruitingFujian Cancer HospitalAug 14, 2026
A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal CancerRegorafenibPhase 1 / Phase 2Not yet recruitingCSPC Megalith Biopharmaceutical Co.,Ltd.Aug 6, 2026
A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, Fluorouracil and IrinotecanRegorafenibPhase 3Not yet recruitingSichuan Baili Pharmaceutical Co., Ltd.Jul 28, 2026
Venetoclax in Association With 3+7 and Midostaurin in FLT3-mutated Acute Myeloid LeukemiaMidostaurinPhase 1 / Phase 2Not yet recruitingUniversity Hospital, BordeauxJul 24, 2026
IBI363 Combined With Bevacizumab for Advanced Colorectal CancerRegorafenibPhase 3RecruitingInnovent Biologics (Suzhou) Co. Ltd.Jul 23, 2026
Antifibrotic Therapy Decision-Making in Pulmonary FibrosisNintedanib—Not yet recruitingBristol-Myers SquibbJul 23, 2026
Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat SyndromeRegorafenibPhase 2Not yet recruitingXiang-QianJul 9, 2026
A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and PimitespibRegorafenib, SunitinibPhase 2RecruitingGlaxoSmithKlineJul 8, 2026
Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary FibrosisNintedanibPhase 2RecruitingMannkind CorporationJul 1, 2026
An Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therapy in HRD-positive Advanced Ovarian CancerSunitinibPhase 2RecruitingBai-Rong XiaJun 25, 2026
Camrelizumab With Famitinib for Patients With Rare Head and Neck MalignanciesFamitinibPhase 1 / Phase 2RecruitingShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityJun 23, 2026
Camrelizumab Combined With Famitinib Malate and Chemotherapy for Treatment of Recurrent/ Metastatic Cervical CancerFamitinibPhase 2Not yet recruitingHunan Cancer HospitalJun 4, 2026
A Comparison of a Medication Adherence Platform (FORTISKAP™) vs. Usual Care in Subjects on Oral Medications for the Treatment of Interstitial Lung Disease, Sarcoid and Pulmonary HypertensionNintedanib—Not yet recruitingCosmos Rx, IncMay 29, 2026
Nintedanib With or Without Dextromethorphan in Patients With Idiopathic Pulmonary Fibrosis (IPF)NintedanibPhase 2Not yet recruitingFirst Affiliated Hospital of Wenzhou Medical UniversityMay 13, 2026
Salvage Haploidentical HSCT With DLI and Targeted Therapy for R/R AMLMidostaurin—Not yet recruitingUnion Hospital, Tongji Medical College, Huazhong University of Science and TechnologyMay 7, 2026
Clinical Study of Novel Therapeutic Vaccine for Advanced Solid TumorsRegorafenibPhase 1RecruitingWest China HospitalMay 5, 2026
Phase 2 Study Of Imetelstat for Patient With Myelodysplastic/Myeloproliferative NeoplasmsMotesanibPhase 2Not yet recruitingM.D. Anderson Cancer CenterApr 24, 2026
Study of SA+X in the Treatment of Newly Diagnosed AMLQuizartinibPhase 2RecruitingRuijin HospitalApr 23, 2026
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of HSK44459 Tablets in Patients With Idiopathic Pulmonary FibrosisNintedanibPhase 3Not yet recruitingHaisco Pharmaceutical Group Co., Ltd.Apr 9, 2026
Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal MelanomaFamitinibPhase 2Not yet recruitingShanghai Zhongshan HospitalApr 8, 2026
Double Immunosuppression With or Without Anti-fibrotic in Scleroderma ILDNintedanib—RecruitingUniversity of PatrasMar 24, 2026
Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)QuizartinibPhase 3RecruitingPETHEMA FoundationMar 18, 2026
A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With OsteosarcomaSunitinibPhase 2RecruitingMemorial Sloan Kettering Cancer CenterMar 17, 2026
A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Radical Resection of Cervical CancerFamitinibNot applicableNot yet recruitingJin LIMar 12, 2026
A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue SarcomasPazopanibPhase 1RecruitingM.D. Anderson Cancer CenterMar 3, 2026
FLT3-ITD Targeted Therapy in Fit AML PatientsMidostaurin, QuizartinibPhase 2 / Phase 3Not yet recruitingEuropean Organisation for Research and Treatment of Cancer - EORTCFeb 23, 2026
Imetelstat Combinations in Relapsed AMLMotesanibPhase 1RecruitingDouglas TremblayJan 6, 2026
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib TherapySunitinibPhase 3RecruitingGlaxoSmithKlineOct 21, 2025
Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS PatientsMasitinibPhase 3Not yet recruitingAB ScienceSep 16, 2025
A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKISunitinibPhase 3Not yet recruitingPeking University Cancer Hospital & InstituteSep 10, 2025
A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell CarcinomaPazopanibPhase 2RecruitingImbioray (Hangzhou) Biomedicine Co., Ltd.Jul 25, 2025
Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)PazopanibPhase 1 / Phase 2RecruitingTianjin Medical University Second HospitalMar 26, 2025
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete RemissionQuizartinibPhase 2RecruitingDaiichi SankyoFeb 13, 2025
Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or AdolescentsPazopanibPhase 2RecruitingShandong Cancer Hospital and InstituteFeb 10, 2025
Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid LeukemiaQuizartinibPhase 1RecruitingM.D. Anderson Cancer CenterJan 10, 2025
Fatty Liver and Pancreatic SteatosisBecaplermin—Not yet recruitingMaria Marta PiskorzJan 3, 2025
Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment ExhaustionPazopanibPhase 2RecruitingTianjin Medical University Second HospitalDec 18, 2024
Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)PazopanibPhase 3RecruitingSun Yat-sen UniversityDec 10, 2024
Revumenib in Combination With 7+3 + Midostaurin in AMLMidostaurinPhase 1RecruitingRichard Stone, MDMar 15, 2024
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)SeralutinibPhase 3RecruitingGossamer Bio USA, Inc.Feb 23, 2024
A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)PazopanibPhase 3RecruitingIntensity Therapeutics, Inc.Feb 16, 2024
Multi-peptide Vaccination Adjuvanted With XS15 in Acute Myeloid Leukemia PatientsMidostaurinPhase 1RecruitingUniversity Hospital TuebingenFeb 9, 2024
A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to TherapyMotesanibPhase 1RecruitingChildren's Oncology GroupFeb 8, 2024
Masitinib in Patients With Mild Alzheimer's DiseaseMasitinibPhase 3Not yet recruitingAB ScienceOct 3, 2022
Rh-PDGF vs EMD for Treatment of Intra-bony DefectsBecaplerminPhase 1 / Phase 2RecruitingNova Southeastern UniversityJul 1, 2022
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With MyelofibrosisMotesanibPhase 1Active, not recruitingGeron CorporationMay 12, 2022
Ridge Augmentation Using Allograft Particles Hydrated With or Without Recombinant Human Platelet-Derived Growth FactorBecaplerminNot applicableRecruitingUniversity of Alabama at BirminghamJul 8, 2021
Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)Midostaurin—RecruitingAcute Leukemia French AssociationMar 2, 2021
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic AgentsCediranibPhase 2Active, not recruitingNational Cancer Institute (NCI)Feb 5, 2021
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor TreatmentMotesanibPhase 3Active, not recruitingGeron CorporationOct 6, 2020
A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical CancerCediranibPhase 2Active, not recruitingThe Clatterbridge Cancer Centre NHS Foundation TrustJul 27, 2020
Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)MidostaurinPhase 1 / Phase 2RecruitingTechnische Universität DresdenMay 12, 2020
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast CancerCediranibPhase 2RecruitingM.D. Anderson Cancer CenterSep 16, 2019
Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid TumorsCediranibPhase 2Active, not recruitingUniversity Health Network, TorontoFeb 22, 2019
WIRE - Novel Treatments in Renal Cell CancerCediranibPhase 2RecruitingCCTU- Cancer ThemeNov 14, 2018
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib AloneCediranibPhase 2Active, not recruitingNational Cancer Institute (NCI)Sep 7, 2018
Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing TherapyCediranibPhase 2Active, not recruitingAstraZenecaNov 7, 2017
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS PatientsMasitinibPhase 3RecruitingAB ScienceApr 25, 2017
Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent GlioblastomaCediranibPhase 2Active, not recruitingNational Cancer Institute (NCI)Nov 28, 2016
Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)MotesanibPhase 2 / Phase 3Active, not recruitingGeron CorporationNov 6, 2015

Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2095189, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.